JERSEY CITY, N.J.--(BUSINESS WIRE)--Quantum Genomics Corp. (QGC), a global biotech company developing new drugs for metabolic and cardiovascular diseases, announced partnership agreements with Inserm, the French national institute for health and medical research and the CNRS, France’s national center for scientific research, and University Paris Descartes. The agreement brings together some of the best scientific skills in the field of cardiovascular diseases from two leading life science research organizations and a premier university along with biotechnology business experience from QGC, to successfully co-develop innovative drugs.
